JP2018516247A5 - - Google Patents

Download PDF

Info

Publication number
JP2018516247A5
JP2018516247A5 JP2017555557A JP2017555557A JP2018516247A5 JP 2018516247 A5 JP2018516247 A5 JP 2018516247A5 JP 2017555557 A JP2017555557 A JP 2017555557A JP 2017555557 A JP2017555557 A JP 2017555557A JP 2018516247 A5 JP2018516247 A5 JP 2018516247A5
Authority
JP
Japan
Prior art keywords
polypeptide
domain
amino acid
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017555557A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018516247A (ja
JP6894846B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/027424 external-priority patent/WO2016171980A1/en
Publication of JP2018516247A publication Critical patent/JP2018516247A/ja
Publication of JP2018516247A5 publication Critical patent/JP2018516247A5/ja
Application granted granted Critical
Publication of JP6894846B2 publication Critical patent/JP6894846B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017555557A 2015-04-24 2016-04-14 Hiv融合体を標的とするポリペプチド Expired - Fee Related JP6894846B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562152271P 2015-04-24 2015-04-24
US62/152,271 2015-04-24
US201562257474P 2015-11-19 2015-11-19
US62/257,474 2015-11-19
PCT/US2016/027424 WO2016171980A1 (en) 2015-04-24 2016-04-14 Polypeptides targeting hiv fusion

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020174288A Division JP2021035951A (ja) 2015-04-24 2020-10-16 Hiv融合体を標的とするポリペプチド

Publications (3)

Publication Number Publication Date
JP2018516247A JP2018516247A (ja) 2018-06-21
JP2018516247A5 true JP2018516247A5 (cg-RX-API-DMAC7.html) 2019-04-25
JP6894846B2 JP6894846B2 (ja) 2021-06-30

Family

ID=55809237

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017555557A Expired - Fee Related JP6894846B2 (ja) 2015-04-24 2016-04-14 Hiv融合体を標的とするポリペプチド
JP2020174288A Pending JP2021035951A (ja) 2015-04-24 2020-10-16 Hiv融合体を標的とするポリペプチド
JP2023014947A Active JP7465378B2 (ja) 2015-04-24 2023-02-03 Hiv融合体を標的とするポリペプチド

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020174288A Pending JP2021035951A (ja) 2015-04-24 2020-10-16 Hiv融合体を標的とするポリペプチド
JP2023014947A Active JP7465378B2 (ja) 2015-04-24 2023-02-03 Hiv融合体を標的とするポリペプチド

Country Status (25)

Country Link
US (2) US10407490B2 (cg-RX-API-DMAC7.html)
EP (2) EP3286212B1 (cg-RX-API-DMAC7.html)
JP (3) JP6894846B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170138558A (cg-RX-API-DMAC7.html)
CN (1) CN107922474A (cg-RX-API-DMAC7.html)
AU (2) AU2016252008B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017022790A2 (cg-RX-API-DMAC7.html)
CA (1) CA2983276A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017002687A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017011583A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170482A (cg-RX-API-DMAC7.html)
DO (1) DOP2017000246A (cg-RX-API-DMAC7.html)
EA (1) EA035332B1 (cg-RX-API-DMAC7.html)
ES (1) ES2884267T3 (cg-RX-API-DMAC7.html)
HK (1) HK1243432A1 (cg-RX-API-DMAC7.html)
IL (1) IL255122A0 (cg-RX-API-DMAC7.html)
MA (2) MA41943A (cg-RX-API-DMAC7.html)
MX (1) MX2017013687A (cg-RX-API-DMAC7.html)
PE (1) PE20180162A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017501914A1 (cg-RX-API-DMAC7.html)
PT (1) PT3286212T (cg-RX-API-DMAC7.html)
SG (1) SG11201708441RA (cg-RX-API-DMAC7.html)
TW (1) TW201643185A (cg-RX-API-DMAC7.html)
UY (1) UY36650A (cg-RX-API-DMAC7.html)
WO (1) WO2016171980A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106755100A (zh) * 2017-02-20 2017-05-31 李因传 可控性hiv‑1基因组靶向编辑系统和其靶向载运系统
WO2019123262A1 (en) 2017-12-18 2019-06-27 VIIV Healthcare UK (No.5) Limited Antigen binding polypeptides
CN114605505B9 (zh) 2018-08-09 2025-04-29 东莞市朋志生物科技有限公司 用于检测hiv-1的合成肽
WO2021081515A2 (en) * 2019-10-25 2021-04-29 Cidara Therapeutics, Inc. Compositions and methods for the treatment of human immunodeficiency virus
EP4397748A4 (en) * 2021-08-30 2025-09-17 Kanglin Biotechnology Hangzhou Co Ltd GENE SEQUENCE CONSTRUCTION FOR GENE THERAPY AGAINST HIV INFECTION

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
IL131016A (en) 1997-01-21 2004-12-15 Gen Hospital Corp Selection of proteins using RNA-protein blends
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
AU2265701A (en) * 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
CA2416219C (en) 2000-07-11 2016-10-11 Research Corporation Technologies, Inc. Artificial antibody polypeptides
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
AU2003299085B2 (en) * 2002-09-27 2008-04-10 Tanox, Inc. Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
CN102816241B (zh) 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
AR067584A1 (es) 2007-07-20 2009-10-14 Hoffmann La Roche Un conjugado de un anticuerpo contra la cd4 y peptidos antifusogenicos
AU2008345424A1 (en) 2007-12-27 2009-07-09 Novartis Ag Improved fibronectin-based binding molecules and their use
CN102076713B (zh) 2008-05-02 2015-03-25 诺华股份有限公司 改进的基于纤连蛋白的结合分子及其用途
MX2011004550A (es) 2008-10-31 2011-07-20 Centocor Ortho Biotech Inc Composiciones de de supercóntigos a base de dominios de fibronectina tipo iii, métodos y usos.
GB0920944D0 (en) * 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
US20130108653A1 (en) 2009-12-22 2013-05-02 Shervin Bahrami Bivalent molecules for hiv entry inhibition
DK2558491T3 (en) 2010-04-13 2018-10-15 Bristol Myers Squibb Co Fibronectin-based Scaffold domain proteins that bind PCSK9
TW201138808A (en) * 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
RU2012148816A (ru) * 2010-05-07 2014-06-20 Ф. Хоффманн-Ля Рош Аг Метод диагностики для определения клеток ex vivo
EP2655411A1 (en) 2010-12-22 2013-10-30 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind il-23
WO2012159164A1 (en) 2011-05-23 2012-11-29 Phylogica Limited Method of determining, identifying or isolating cell-penetrating peptides
MX358827B (es) 2011-09-27 2018-09-05 Janssen Biotech Inc Supercóntigos de proteína basados en repeticiones de fibronectina tipo iii con superficies de unión alternativas.
US20150361159A1 (en) * 2013-02-01 2015-12-17 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
US20160152686A1 (en) * 2013-03-13 2016-06-02 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
CN103333255A (zh) 2013-06-28 2013-10-02 复旦大学 一种长效hiv‐1膜融合抑制剂

Similar Documents

Publication Publication Date Title
JP7682150B2 (ja) プロテアーゼ活性化治療剤を含む組成物および方法
JP2016000731A5 (cg-RX-API-DMAC7.html)
JP2014530253A5 (cg-RX-API-DMAC7.html)
JP2024102211A5 (cg-RX-API-DMAC7.html)
JP2015509097A5 (cg-RX-API-DMAC7.html)
JP2013506411A5 (cg-RX-API-DMAC7.html)
ES3064850T3 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
JP2023504914A5 (cg-RX-API-DMAC7.html)
JP2017527272A5 (cg-RX-API-DMAC7.html)
JP2018522563A5 (cg-RX-API-DMAC7.html)
JP2015522576A5 (cg-RX-API-DMAC7.html)
JP2019531093A5 (cg-RX-API-DMAC7.html)
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
JP2016052315A5 (cg-RX-API-DMAC7.html)
JP2017514522A5 (cg-RX-API-DMAC7.html)
JP2013534812A5 (cg-RX-API-DMAC7.html)
JP2014526881A5 (cg-RX-API-DMAC7.html)
JP2020517658A5 (cg-RX-API-DMAC7.html)
JP2009520758A5 (cg-RX-API-DMAC7.html)
JP2020524141A5 (cg-RX-API-DMAC7.html)
JP2017534296A5 (cg-RX-API-DMAC7.html)
WO2001043779A3 (en) Anti-hiv-1 conjugates for treatment of hiv disease
JP2013520487A5 (cg-RX-API-DMAC7.html)
JP2016535741A5 (cg-RX-API-DMAC7.html)
JP2020530300A5 (cg-RX-API-DMAC7.html)